IP Library Granted Patent US 12,594,312
Granted Patent B2
US 12,594,312 · App. 17/241,957 · Granted Apr 7, 2026

Bacteriophage compositions for treating

Inventors: Sebastien Lemire (Culver City, CA); Stacey Lynn Kolar (Los Angeles, CA); Brian C. Varnum (Santa Monica, CA); Sandra P. Morales (Sydney, AU)
Assignee: Armata Pharmaceuticals, Inc.
A61K35/76A61K45/06A61P31/04C12N7/00C12N2795/10121C12N2795/10132C12N2795/10171C12N2795/10221C12N2795/10232C12N2795/10271
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,594,312
App. No.
17/241,957
Granted
Apr 7, 2026
Kind
B2
Abstract

The present disclosure relates to bacteriophages and compositions capable of infecting and killing Pseudomonas , and use of the same for treating Pseudomonas , e.g. Pseudomonas aeruginosa , bacterial infections.

Claims (21)

1 . A method of treating a bacterial infection comprising administering a composition comprising a bacteriophage comprising a polynucleotide sequence with at least 94% identity to SEQ ID NO: 6.

2 . The method of claim 1 , wherein the composition further comprises at least one additional bacteriophage.

3 . The method of claim 1 , the composition comprising two or more bacteriophages, wherein the composition further comprises at least one bacteriophage comprising a polynucleotide sequence with at least 97% identity to SEQ ID NO: 1, a polynucleotide sequence with at least 95% identity to SEQ ID NO: 3, or a polynucleotide sequence with at least 94% identity to SEQ ID NO: 4.

4 . The method of claim 1 , the composition comprising three or more bacteriophages, wherein the composition further comprises at least two bacteriophages comprising a polynucleotide sequence with at least 97% identity to SEQ ID NO: 1, a polynucleotide sequence with at least 95% identity to SEQ ID NO: 3, or a polynucleotide sequence with at least 94% identity to SEQ ID NO: 4.

5 . The method of claim 1 , the composition further comprising a bacteriophage comprising a polynucleotide sequence with at least 97% identity to SEQ ID NO: 1, a bacteriophage comprising a polynucleotide sequence with at least 95% identity to SEQ ID NO: 3, and a bacteriophage comprising a polynucleotide sequence with at least 94% identity to SEQ ID NO: 4.

6 . The method of claim 1 , wherein the bacteriophage comprises a polynucleotide sequence with at least 95% sequence identity to SEQ ID NO:6.

7 . The method of claim 6 wherein the bacteriophage comprises a polynucleotide sequence with at least 96% sequence identity SEQ ID NO:6.

8 . The method of claim 7 , wherein the bacteriophage comprises a polynucleotide sequence with at least 97% sequence identity to SEQ ID NO:6.

9 . The method of claim 7 , wherein the bacteriophage comprises a polynucleotide sequence with at least 98% sequence identity to SEQ ID NO:6.

10 . A method of treating a bacterial infection comprising administering a composition comprising two or more bacteriophages comprising a first bacteriophage comprising a polynucleotide sequence with at least 94% identity to SEQ ID NO: 6, and one or more additional bacteriophages comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 3, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 4, or a polynucleotide sequence with at least 90% identity to SEQ ID NO: 18.

11 . The method of claim 10 , comprising administering a composition comprising two or more bacteriophages comprising a first bacteriophage comprising a polynucleotide sequence with at least 94% identity to SEQ ID NO: 6, and one or more additional bacteriophages comprising a polynucleotide sequence with at least 99% identity to SEQ ID NO: 1, a polynucleotide sequence with at least 98% identity to SEQ ID NO: 3, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 4, or a polynucleotide sequence with at least 95% identity to SEQ ID NO: 20.

12 . The method of claim 1 , wherein the composition comprises one or more additional bacteriophage comprising a polynucleotide sequence having at least 90% identity to a polynucleotide sequence selected from: SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and/or SEQ ID NO: 22.

13 . The method of claim 1 , wherein the composition's target bacteria range is broader than the cumulative range of the individual bacteriophage in the composition, and wherein the target bacteria range is broadened within the bacterial species that the bacteriophage is able to infect.

14 . The method of claim 12 , wherein the one or more additional bacteriophage comprises a polynucleotide sequence with at least a 90% identity to SEQ ID NO: 7, a polynucleotide with at least a 93% identity to SEQ ID NO: 8, a polynucleotide sequence with at least 93% identity to SEQ ID NO: 9, a polynucleotide sequence with at least 89% identity to SEQ ID NO: 10, a polynucleotide sequence with at least 95% identity to SEQ ID NO: 11, a polynucleotide sequence with at least 91% identity to SEQ ID NO: 12, a polynucleotide sequence with at least 92% identity to SEQ ID NO: 13, a polynucleotide sequence with at least 96% identity to SEQ ID NO: 14 a polynucleotide sequence with at least 95% identity to SEQ ID NO: 15, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 16, a polynucleotide sequence with at least 92% identity to SEQ ID NO: 17, a polynucleotide sequence with at least 95% identity to SEQ ID NO: 18, a polynucleotide sequence with at least 96% identity to SEQ ID NO: 19, a polynucleotide sequence with at least 96% identity to SEQ ID NO: 20, a polynucleotide sequence with at least 96% identity to SEQ ID NO: 21, or a polynucleotide sequence with at least 95% identity to SEQ ID NO: 22.

15 . The method of claim 1 , wherein the bacteriophage is resistant to sputum inactivation.

16 . The method of claim 1 , wherein the bacterial infection comprises a pulmonary infection, and/or rhinosinusitis.

17 . The method of claim 1 , wherein the bacterial infection in in the presence of cystic fibrosis, non-cystic fibrosis bronchiectasis (NCFB), a lung fibrosis condition and/or pneumonia.

18 . The method of claim 3 , wherein the composition further comprises a bacteriophage comprising a polynucleotide sequence with at least 97% identity to SEQ ID NO: 1.

19 . The method of claim 3 , wherein the composition further comprises a bacteriophage comprising a polynucleotide sequence with at least 95% identity to SEQ ID NO: 3.

20 . The method of claim 3 , wherein the composition further comprises a bacteriophage comprising a polynucleotide sequence with at least 94% identity to SEQ ID NO: 4.

21 . The method of claim 1 , wherein the bacteriophage comprises a polynucleotide sequence with at least 99% sequence identity to SEQ ID NO:6.

Assignments (8)
SECURITY INTEREST Recorded May 20, 2026
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 074715/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2026
From: MORALES, SANDRA P.
To: ARMATA PHARMACEUTICALS, INC.
Reel/Frame 073761/0688 →
SECURITY INTEREST Recorded Aug 14, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 072025/0567 →
SECURITY INTEREST Recorded Mar 17, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 070532/0979 →
SECURITY INTEREST Recorded Mar 5, 2024
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 066657/0409 →
SECURITY INTEREST Recorded Jul 14, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 064262/0958 →
SECURITY INTEREST Recorded Feb 17, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 062733/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2022
From: LEMIRE, SÉBASTIEN; KOLAR, STACEY LYNN; VARNUM, BRIAN CLARKE
To: ARMATA PHARMACEUTICALS, INC.
Reel/Frame 059542/0224 →
Continuity (2)
Provisional Application 63016132 · Apr 27, 2020
Related Publication 20210330722A1 · Oct 28, 2021
References Cited (27)
US 20230174954A1 · Lemire · 2023 [cited by examiner]
US 20240226205A1 · Lemire et al. · 2024 [cited by applicant]
CN 104519893A · 2015 [cited by applicant]
CN 110612349A · 2019 [cited by applicant]
CN 110691603A · 2020 [cited by applicant]
EP 2865383A1 · 2015 [cited by applicant]
EP 3018201A1 · 2016 [cited by applicant]
JP 2016537405A · 2016 [cited by applicant]
JP 2017534684A · 2017 [cited by applicant]
WO 2019136108A1 · 2019 [cited by applicant]
WO 2021222257A1 · 2021 [cited by applicant]
Essoh C, Latino L, et al Investigation of a Large Collection of Pseudomonas aeruginosa Bacteriophages Collected from a Single Environmental Source in Abidjan, Côte d'Ivoire. PLoS One. Jun. 26, 2015;10(6):e01305 (Year: 2… [cited by examiner]
Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect. Aug. 2008;38(8):426-30. doi: 10.1016/j.medmal.2008.06.023. Epub Aug. 6, 2008. PMID: 18687542. (Year: 2008). [cited by examiner]
Forti F, Roach DR, et al. Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models. Antimicrob Agents Chemother. May 25, 2018;62(6):e02… [cited by examiner]
Pseudomonas phage vB_PaeP_PAO1_1-15pyo, complete genome NCBI Reference Sequence: NC_047967.1 (Year: 2015). [cited by examiner]
Pseudomonas phage vB_PaeM_E215, complete genome NCBI Reference Sequence: NC_042080.1 (Year: 2019). [cited by examiner]
Pseudomonas phage PAK_P1, complete genome NCBI Reference Sequence: NC_015294.2 (Year: 2010). [cited by examiner]
Pseudomonas phage PAK_P4, complete genome NCBI Reference Sequence: NC_022986.1 (Year: 2013). [cited by examiner]
Can K, Aksu U, Yenen OŞ. Investigation of PhiKZ phage therapy against Pseudomonas aeruginosa in mouse pneumonia model. Turk J Med Sci. Jun. 14, 2018;48(3):670-678. (Year: 2018). [cited by examiner]
Genbank: MK837012.1 (2019) Pseudomonas virus Pa223 (Year: 2019). [cited by examiner]
Genbank: MN615701.1 (2019) Pseudomonas phage vB PaeM SMS21 (Year: 2019). [cited by examiner]
Genbank: NC_047953.1 (2018) Pseudomonas phage vB PaeP 130_113 (Year: 2018). [cited by examiner]
Genbank: MK340761 (2019) Pseudomonas phage vB PaeM SCUT-S2 (Year: 2019). [cited by examiner]
Thompson et al. (Nov. 11, 1994) “Clustal W: Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice”, Nucleic Acids Resea… [cited by applicant]
Walle et al. (Jun. 12, 2004) “Align-M-A New Algorithm for Multiple Alignment of Highly Divergent Sequences, Bioinformatics”, 20(9):1428-1435. [cited by applicant]
Invitation to Pay Additional fees received for PCT Patent International Application No. PCT/US2021/029412, mailed on Aug. 4, 2021, 6 pages. [cited by applicant]
Ceyssens et al.(Nov. 2009) “Comparative Analysis of the Widespread and Conserved PB1-like Viruses Infecting Pseudomonas Aeruginosa”,Environmental Microbiology,11(11):2874-2883. [cited by applicant]